Published in J Urol on April 30, 2013
Active surveillance for prostate cancer: current evidence and contemporary state of practice. Nat Rev Urol (2016) 1.21
Conditional probability of reclassification in an active surveillance program for prostate cancer. J Urol (2015) 0.92
Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol (2014) 0.91
Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer. Eur Radiol (2014) 0.89
Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. Am Soc Clin Oncol Educ Book (2016) 0.81
Active surveillance for prostate cancer. Int J Urol (2015) 0.80
Pathological characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens. Prostate (2014) 0.79
Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy. J Clin Oncol (2016) 0.79
PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Mod Pathol (2016) 0.78
Should Gleason 6 be labeled as cancer? Curr Opin Urol (2015) 0.78
Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol (2013) 0.76
Long-term outcomes of nonpalpable prostate cancer (T1c) patients treated with radical prostatectomy. Prostate Int (2015) 0.75
Editorial comment. J Urol (2013) 0.75
Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols. J Korean Med Sci (2015) 0.75
Active surveillance for intermediate-risk prostate cancer. Prostate Cancer Prostatic Dis (2016) 0.75
Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience. Ecancermedicalscience (2016) 0.75
Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int (2014) 0.75
Tools to identify the men with prostate cancer most appropriate for active surveillance? Asian J Androl (2013) 0.75
Difference of opinion - Active surveillance in intermediate risk prostate cancer: is it safe? Opinion: Yes. Int Braz J Urol (2016) 0.75
Editorial comment. J Urol (2013) 0.75
Five-year follow-up of active surveillance for prostate cancer: A Canadian community-based urological experience. Can Urol Assoc J (2014) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst (2003) 11.27
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol (2009) 10.43
Overdiagnosis in cancer. J Natl Cancer Inst (2010) 10.31
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA (1994) 9.15
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med (2012) 3.44
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol (2012) 2.70
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68
Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol (2010) 2.65
Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol (2009) 2.39
The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw (2010) 2.08
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol (2010) 1.91
Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol (2007) 1.82
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int (2009) 1.56
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal (2010) 1.16
Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology (2008) 1.12
Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int (2011) 1.10
Expert panel advocates surveillance for men with low-risk prostate cancer. JAMA (2012) 0.90
Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes. Curr Urol Rep (2012) 0.88
Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. J Urol (2012) 0.87
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Complications after prostate biopsy: data from SEER-Medicare. J Urol (2011) 5.40
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. J Urol (2012) 4.11
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res (2004) 3.29
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Baseline prostate-specific antigen testing at a young age. Eur Urol (2011) 2.95
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. J Urol (2007) 2.78
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology (2010) 2.54
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51
What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol (2010) 2.49
Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol (2009) 2.45